Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said. CVS Health also said Thursday that it will start selling Wegovy at a ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.